Vanguard Capital Management filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a 4.97% stake in Collegium Pharmaceutical Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported beneficial ownership of 1,621,026 shares of Collegium Pharmaceutical Inc common stock.
  • Percent of class: The 1,621,026 shares represent 4.97% of the outstanding class of common stock, as disclosed in the filing.
  • Sole voting power: Vanguard reported sole voting power over 245,798 shares, with zero shares subject to shared voting power.
  • Sole dispositive power: The filing attributes sole dispositive power over the full 1,621,026 shares to Vanguard Capital Management, with no shared dispositive power reported.
  • Event date: The ownership event that triggered this amendment occurred on September 30, 2026, according to the filing.
  • Reporting person: The statement was signed by My Trieu-Gatt, identified as Authorized Signatory and Head of Global Fund Administration at Vanguard Capital Management.

Vanguard Capital Management Amends Its Position in Collegium Pharmaceutical

Vanguard Capital Management, an investment adviser organized in Pennsylvania and headquartered at 100 Vanguard Blvd, Malvern, PA, filed Amendment No. 1 to its beneficial ownership statement covering common stock of Collegium Pharmaceutical Inc (NASDAQ:COLL), a specialty pharmaceutical company whose principal executive offices are located at 100 Technology Center Dr, Suite 300, Stoughton, MA 02072. The filing covers shares with CUSIP number 19459J104 and reflects ownership as of the event date of September 30, 2026.

According to the filing, the aggregate amount beneficially owned by Vanguard Capital Management is 1,621,026 shares, equal to 4.97% of the class. The filing notes that sole voting power applies to only 245,798 of those shares, while sole dispositive power extends to all 1,621,026 shares. No shared voting or shared dispositive power was reported. Item 5 of the filing confirms that this represents ownership of 5 percent or less of the class.

The filing also discloses that the reported position encompasses securities held by Vanguard funds or sleeves thereof, as well as securities held by clients of certain Vanguard affiliates, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd. The filing states that Vanguard Capital Management certified the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Vanguard Capital Management disclosed an amended beneficial ownership position of 1,621,026 shares, or 4.97%, of Collegium Pharmaceutical Inc common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 245,798 shares.